Scientists engineer bacteria to destroy cancer tumors from oxygen-starved cores where chemotherapy fails, using smart genetic controls for safety.

An unexpected discovery may bring scientists closer to a long-sought goal: finding an ideal immunotherapy target for solid tumors.

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...

HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...

Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why these cancers are difficult to treat, including mutations they may express or ...

Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically ...

Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Gram-stained section of a macrophage with ingested S epidermidis bacteria, seen as purple granules within its cytoplasm. In this stain, the nucleus appears pale, with a reddish nucleolus. It is ...

DEAR DR. ROACH: Can you define the characteristics of the four stages of cancer? I understand that stage I is generally when cancer is caught early and can be treated with a good success rate, while ...